



B

B

HBsAg -

AntiHBs -

HBsAg

% -

HBV-DNA -

DNA

in vitro in vivo

Anti-HCV HBeAb HBsAg HBsAg -

HBV-DNA

HDL LDL PTT PT SLT ALT %

%

( )

B

b

B

b

HBV-DNA -

( ) (

ALT -

HBsAg -

HBV-DNA -

b

RBC WBC) CBC

MCH MCV

(MCHC

B

/

HBV-DNA HBsAg

( )

Knodell

HBV ( )

/

( )

B

HBV- % HBeAb HBeAg B

DNA-PCR PCR e B

PCR assay e

PCR e

AntiHBe PCR ( HBeAb) ALT

HBV-DNA HBsAg ALT HBsAb ALT

b a b a B HBV PCR

HBV-DNA

( )

YMDD B B e

YMDD B

YMDD ( )

YMDD B

YMDD

HBV b / B

( )

a

B

( )

HBV

b

B

( ) HBeAg

)b

(

HBV

( )

\*\*\*\*\*

B

B

( )

HBV

( )

Pegylated

\_\_\_\_\_  
Peg-interferon  
Adefovir  
Paroxetine

**References:**

- 1- Stephanus G. Hadziyannis, Nicolaos C. Tassopoulos, E. Gennyheathcote: Adefovir Dipivoxil for the treatment, of Hepatitis B e antigen, Neg Chronic Hep.13, N.E.G.M., Vol. 348, Feb 27, 2003; 800–807.
- 2- Mark E., Mailliard, John L., Gollan, M.D.: Suppressing Hep. B without resistance so far, so Good, N.E.G.M., Vol. 348, Feb 27, 2003; 848-850.
- 3- Patrick Marcellin, Ting Tsumg Chang, Seng Gee Lim, et al: Adefovir Dipivoxil for treatment of Hepatitis B e antigen-positive chronic Hepatitis B, N.E.J.M., Vol. 348, Feb 27, 2003; 808-816.
- 4- Figen GuraKan, Nurtenkocak, Hasan Ögen: comparison of standard and high dosage recombinant INF  $\alpha$ -2b for treatment of children with children with chronic Hep. B. Inf. Ped. Inf. Dis. J., Vol. 19, Jan 2000; 59-56.
- 5- Kohachiro Sugiyama, Kenji Goto, Yoshishige Miyake, Toshihiro Ando, et al: Hepatitis B Core promoter or precore gene Mutations related to age at peroconversion from hepatitis B e Antigen to anti – Hepatitis B e in Japanese Children, Ped. Inf. Dis. J., Vol. 18, Nov 2000; 1101-1103.
- 6- Corina Hartman, Dorora Berkowitz, Daniel Shouval, et al: lamivudine treatment for chronic Hep. B, infection in children unresponsive to interferon, Ped. Inf. Dis. J., Vol. 22, NO. 3, March 2003; 224-998.
- 7- Leung N.W., Lai C.L., Guan R., Liaw Y.F.: The effect of longer duration of harbouring lamivudine- resistant hepatitis B Virus (YMDD mutants) on liver hiotiology during 3 years lamivudine therapy in Chinese patients. Hepatology 2001; 34: 348 A.
- 8- Hwai-L Yang, Sheng-Nan Lu, Yun-Fan Liaw, San Lin You: Hepatitis B e antigen and the risk of hepatoeclluar carcinoma, N. Eng. J. Med. Vol. 347, July 18 2002; 168-174.
- 9- T. Jake Liong, Marc Ghony: Hepatitis B e antigen – the dangerous endgame of hepatitis B., N. Eng. J. Med., Vol. 347, July 18 2002; 908-910.
- 10- Anna S.F. Lok, M.D.: Chronic Hepatitis B., N. Eng. J. Med., Vol. 346, May 30, 2002; 1689-3.
- 11- Maureen M. Jonas, Deirdre A. Kelly, Jack Mizerski, Isabel B. Badia: International pediatric lamivudine investigator group. N. Eng. J. Med. Vol. 346, May 30 2002; 1706-1713.
- 12- Jara P., Bortolotti F.: INF  $\alpha$  treatment of chronic, Hep. B in childhood: a consensus advice based an experience in European children, J Ped Gastroenterology Nutr, 1999; 94: 163-70.
- 13- Malik A., Lee W.M.: Chronic Hep. B Virus infection: Treatment strategy for the next millennium. Ann. Int. Med., 2000; 139: 793-31.
- 14- Dominique L. Mussleman, David H. Lawson, Jane F. Gumnick: Paroxetine for the

prevention of depression induced by high-dose interferon alpha, N.E.J.M, Vol. 344, No. 13, March 29, 2001; 461-5.

15- MANDELL, DOUGLAS, BENNET Thomas A., SHAW-STIFFEL chronic Hepatitis, Principle and Practice of Inf. Disease, 5<sup>th</sup> edition, Vol. 3, 2000; 1297-1331.

Archive of SID